111 Capital Buys 10,040 Shares of DexCom, Inc. $DXCM

111 Capital grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 62.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,004 shares of the medical device company’s stock after purchasing an additional 10,040 shares during the quarter. 111 Capital’s holdings in DexCom were worth $1,750,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the period. Geode Capital Management LLC raised its stake in shares of DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after acquiring an additional 358,617 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares during the last quarter. Norges Bank bought a new stake in shares of DexCom in the second quarter worth about $453,279,000. Finally, Groupama Asset Managment grew its stake in shares of DexCom by 79,043.1% in the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after purchasing an additional 4,011,438 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 1.3%

NASDAQ:DXCM opened at $73.43 on Monday. The firm has a market capitalization of $28.26 billion, a P/E ratio of 34.97, a PEG ratio of 1.43 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company’s 50-day simple moving average is $70.24 and its 200 day simple moving average is $69.08.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned $0.45 earnings per share. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on DXCM shares. Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, December 16th. Barclays reissued an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a research note on Friday, February 13th. Mizuho raised their price target on DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Citigroup reiterated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Finally, Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.